Recent Advances in the Use of Focused Ultrasound for Magnetic Resonance Image-Guided Therapeutic Nanoparticle Delivery to the Central Nervous System.
Authors: Fisher DG, Price RJ
Targeting systemically-administered drugs and genes to specific regions of the central nervous system (CNS) remains a challenge. With applications extending into numerous disorders and cancers, there is an obvious need for approaches that facilitate the delivery of therapeutics across the impervious blood-brain barrier (BBB). Focused ultrasound (FUS) is an emerging treatment method that leverages acoustic energy to oscillate simultaneously administered contrast agent microbubbles. This FUS-mediated technique temporarily disrupts the BBB, allowing ordinarily impenetrable agents to diffuse and/or convect into the CNS. Under magnetic resonance image guidance, FUS and microbubbles enable regional targeting-limiting the large, and potentially toxic, dosage that is often characteristic of systemically-administered therapies. Subsequent to delivery across the BBB, therapeutics face yet another challenge: penetrating the electrostatically-charged, mesh-like brain parenchyma. Non-bioadhesive, encapsulated nanoparticles can help overcome this additional barrier to promote widespread treatment in selected target areas. Furthermore, nanoparticles offer significant advantages over conventional systemically-administered therapeutics. Surface modifications of nanoparticles can be engineered to enhance targeted cellular uptake, and nanoparticle formulations can be tailored to control many pharmacokinetic properties such as rate of drug liberation, distribution, and excretion. For instance, nanoparticles loaded with gene plasmids foster relatively stable transfection, thus obviating the need for multiple, successive treatments. As the formulations and applications of these nanoparticles can vary greatly, this review article provides an overview of FUS coupled with polymeric or lipid-based nanoparticles currently utilized for drug delivery, diagnosis, and assessment of function in the CNS.
Introduction
Purpose
Drug delivery with BBB opening
Study Objective
To review recent advances in using focused ultrasound combined with polymeric and lipid-based nanoparticles for targeted drug and gene delivery, diagnosis, and functional assessment in the central nervous system.
Animal model / Human subject
Not reported (review article; no experimental organism used)
Disease model
Not applicable — general CNS disorders and cancers (review of focused ultrasound-mediated BBB disruption and nanoparticle delivery)
MRI or image guidance method
magnetic resonance image guidance (MRI)
Targeted brain region(s)
Central Nervous System (Cns)
Target coordinates
Not provided
Cargo name and characteristics
Polymeric or lipid-based nanoparticles — non-bioadhesive, encapsulated nanoparticles engineered for CNS delivery; surface-modified to enhance tissue penetration and targeted cellular uptake, tune pharmacokinetics (drug release, distribution, excretion), and loaded with therapeutic cargos such as small-molecule drugs or gene plasmids for sustained transfection.
Route of administration
Systemic (intravenous) administration
Outcomes and Safety
Summary of Outcomes
MRI-guided focused ultrasound with microbubbles transiently opens the blood–brain barrier to enable spatially targeted, noninvasive delivery of polymeric or lipid nanoparticles carrying drugs or genes into the CNS, improving parenchymal penetration, controlled pharmacokinetics, and therapeutic/diagnostic potential.
Duration of biological effect
not specified
Safety-related matter
The article mentions risks of potentially toxic systemic dosages and adverse delivery of therapeutics but states that FUS combined with biocompatible nanoparticles can mitigate these toxic or adverse effects and that FDA-approved FUS systems are showing promising initial clinical trial results for BBB opening.
Brain Region
Ultrasound Parameters
Ultrasound instrument
Not specified in provided text.
FUS Frequency
Not specified in the provided text
FUS Intensity
Not reported in provided text
FUS Pressure
Not reported
FUS Mode
not specified
Pulse duration
Not reported in provided text
Duration of a single FUS session
Not specified in the provided text
Focal Characteristics
Not specified in the provided text.
Treatment frequency
single session
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search